StockStory.org on MSN
DexCom (NASDAQ:DXCM) exceeds Q1 CY2026 expectations but stock drops
Medical device company DexCom (NASDAQ:DXCM) reported Q1 CY2026 results , with sales up 15% year on year to $1.19 billion. The ...
If you are wondering whether DexCom shares are priced attractively right now or if the stock still carries a premium, this article breaks down what the current market price might be implying about the ...
Barchart on MSN
DexCom’s quarterly earnings preview: What you need to know
San Diego, California-based DexCom, Inc. (DXCM) is a medical technology company focused on continuous glucose monitoring (CGM ...
Pre-earnings options volume in DexCom (DXCM) is 2.4x normal with puts leading calls 7:5. Implied volatility suggests the market is anticipating a move near 6.7%, or $5.59, after results are released.
DexCom (NASDAQ:DXCM) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a snapshot of their recent ratings, ...
DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A robust first-quarter 2024 performance, along with a series of favorable coverage decisions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results